Klaria Pharma Holding AB (FRA:6FN) Revenue: €0.01 Mil (TTM As of Mar. 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
9 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Revenue?

Klaria Pharma Holding AB FRA:6FN +0.94% 9 Revenue is €0.01 Mil as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 9/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Klaria Pharma Holding AB's revenue for the three months ended in Mar. 2026 was €0.01 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01 Mil. Klaria Pharma Holding AB's Revenue per Share for the three months ended in Mar. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.

Warning Sign:

Klaria Pharma Holding AB revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Klaria Pharma Holding AB was -100.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -21.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 12 years, Klaria Pharma Holding AB's highest 3-Year average Revenue per Share Growth Rate was -7.50% per year. The lowest was -21.20% per year. And the median was -14.35% per year.


Klaria Pharma Holding AB  (FRA:6FN) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Klaria Pharma Holding AB Revenue Related Terms


Klaria Pharma Holding AB Revenue Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB Revenue Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.53 0.76 0.20 0.83

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.00 0.00 0.00 0.01

FRA:6FN vs ZTS, UTHR: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klaria Pharma Holding AB Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Revenue distribution charts can be found below:

* The bar in red indicates where Klaria Pharma Holding AB's Revenue falls into.


FRA:6FN
9GF Score
Klaria Pharma Holding AB FRA:6FN
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of €0.01 Mil mean?
Klaria Pharma Holding AB (FRA:6FN) has a Revenue of €0.01 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Klaria Pharma Holding AB and its competitors.
Is Klaria Pharma Holding AB's Revenue too high?
Klaria Pharma Holding AB's current Revenue is €0.01 Mil. Overall, Klaria Pharma Holding AB has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's Revenue compare to ZTS and UTHR?
Klaria Pharma Holding AB's Revenue of €0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current Revenue is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 115.7% above its estimated fair value. The current Revenue is €0.01 Mil. Klaria Pharma Holding AB's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current Revenue is €0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 115.7% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • Revenue: €0.01 Mil
  • GF Value™: €0.03 vs. price of €0.06 (115.7% above fair value)
  • GF Score™: 9/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
9GF Score

Get the complete analysis for FRA:6FN

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value